Micronoma’s microbiome platform is breaking into its next phase with validation from the U.S. Food and Drug Administration.

Last month, the San Diego-based company announced that the FDA has given its OncobiotaLUNG assay Breakthrough Device Designation. The designation ensures the agency will give Micronoma continued guidance and prioritized reviews of its upcoming clinical trial and concomitant pre-market approval processes.

Read more at San Diego Buisness Journal